Resultados de Búsqueda
Patients with long-term immunosuppressants are advised to continue with this treatment during the Covid-19 pandemic.
Evidencias COVID-19
Oxford COVID-19 Evidence Service
The evidence on how to manage people with chronic lung conditions with long-term oral immunosuppression during the Covid-19 pandemic is very limited. There is no evidence to suggest that long-term immunosuppression should be stopped during the current pandemic. If patients show signs of infection, immunosuppression should be discontinued long-term, except for long-term steroids.
ver más ... 2020It is recommended that the nutritional status of each infected patient be evaluated before the administration of general treatments, since the effects of different interventions for COVID-19 are ...
Evidencias COVID-19
IHCAI – DIME. Información seleccionada sobre intervenciones para el tratamiento de COVID-19
This is a systematic review without quantitative analysis describing the effects of potential interventions according to some found literature of various medications including vitamins, minerals, interferons, chloroquine, and other medications. For example, it recognizes some benefit of using interferons from various studies. It also includes chloroquine for its ability to transport zinc. None of the findings is conclusive. In this way the review notes that the nutritional status of each ...
ver más ... 2020It is uncertain that treatment with antihypertensive drugs has to be suspended as it is a risk against COVID-19.
Evidencias COVID-19
IHCAI – DIME. Información seleccionada sobre intervenciones para el tratamiento de COVID-19
Many of the patients infected with COVID-19 are elderly patients who have underlying pathologies (diabetes mellitus, ischemic heart disease), which in turn are risk factors for increased severity and mortality from COVID-19, which is why It is expected that many of them are treated with ACE or AIIRA, without this meaning that antihypertensive treatment itself is the factor that worsens the prognosis of their COVID-19 infection. Patients in treatment with medicines from the ACE or AIIRA group ...
ver más ... 2020There is uncertainty about the efficacy of mHealth due to the complexities of healthcare delivery and human interactions which challenge simplistic conclusions about how healthcare professionals will ...
Evidencias COVID-19
Cochrane - Colección Especial - Coronavirus (Covid-19): asistencia en remoto mediate la telesalud
Perceptions reflect the interaction between technology, contexts, and human attributes. Detailed descriptions of the program, implementation processes, and contexts, along with efficacy studies, will help unravel this interaction to formulate hypotheses about the effectiveness of mHealth.
ver más ... 2020It is uncertain whether chloroquine, hydroxychloroquine, or remdesivir have beneficial effects for the treatment of COVID-19.
Evidencias COVID-19
IHCAI – DIME. Información seleccionada sobre intervenciones para el tratamiento de COVID-19
The results of in vitro studies comparing Chloroquine (CQ) with Hydroxychloroquine in the effort to find a faster solution while investigating remdesivir (GS-5734) are described. A recent case report showed that remdesivir treatment improved the clinical condition of the first SARS-CoV-2 infected patient in the United States, and a Phase III clinical trial of remdesivir against SARS-CoV was launched on February 4. 2 in Wuhan, 2020. However, as an experimental drug, remdesivir is not expected to ...
ver más ... 2020